Scientific work

Doç. Dr. Kadriye Bir Yücel

67 publications. The source of the information is stated next to each publication.

Back to profile

  1. Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15041657 PMID 41753346 2 citations (Europe PMC) Open-access full textSource: OpenAlex

  2. Remnant cholesterol inflammatory index for predicting pathological complete response to neoadjuvant therapy in breast cancer: A multicenter external validation study

    The Breast, 2026

    DOI 10.1016/j.breast.2026.104936 PMID 42777557 Open-access full textSource: ORCID

  3. Claudin 18.2 Positivity Thresholds and Candidate Populations for Targeted Therapy in Pancreatic Ductal Adenocarcinoma: A Real-World Retrospective Cohort

    Cancers, 2026

    DOI 10.3390/cancers18172827 PMID 42738347 Open-access full textSource: OpenAlex

  4. Predicting Pathologic Response in Locally Advanced Rectal Cancer Using Inflammatory, Nutritional, and Sarcopenia-Based Markers: A Regression and AI-Based Analysis (CINR-AI Study)

    Clinical Colorectal Cancer, 2026

    DOI 10.1016/j.clcc.2025.10.002 PMID 41198426 1 citation (Europe PMC) Source: ORCID

  5. Baseline 25-hydroxyvitamin D and progression-free survival in de novo metastatic hormone-sensitive prostate cancer: prognostic model development and external validation

    The oncologist, 2026

    DOI 10.1093/oncolo/oyag396 PMID 42836684 Open-access full textSource: Europe PMC

  6. Structural Acceleration in Sepsis-Associated Cancer Mortality in an Aging Population: A Nationwide Study in the United States, 1999–2020

    SSRN Electronic Journal, 2026

    DOI 10.2139/ssrn.6201853 Open-access full textSource: OpenAlex

  7. Temporal Trends and Demographic Disparities in Prostate Cancer Mortality in the United States, 1999-2020: A CDC WONDER Analysis

    Acta haematologica oncologica Turcica., 2026

    DOI 10.4274/ahot.galenos.2026.2026-8-1 Open-access full textSource: OpenAlex

  8. Quality of Life and Patient-Reported Outcomes During First-Line Chemotherapy in Older Patients with De Novo Metastatic Gastrointestinal Cancers: A Prospective Longitudinal Study

    Healthcare, 2026

    DOI 10.3390/healthcare14203458 PMID 42940505 Open-access full textSource: ORCID

  9. C-Reactive Protein–Albumin–Lymphocyte Index and the Modified Glasgow Prognostic Score as Predictors of Early Mortality After Palliative Percutaneous Transhepatic Biliary Drainage in Malignant Biliary Obstruction

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15124608 PMID 42355776 Open-access full textSource: ORCID

  10. Wearable-derived postdischarge mobility as a digital biomarker for 90-day readmission and mortality in metastatic cancer

    Supportive Care in Cancer, 2026

    DOI 10.1007/s00520-026-11216-6 PMID 42726154 Source: OpenAlex

  11. Re: Factors associated with employment outcomes in cancer survivors: a systematic scoping review spanning a decade of international research

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026

    DOI 10.1007/s00520-026-10716-9 PMID 42043612 Source: Europe PMC

  12. Impact of vitamin D deficiency and inflammatory biomarkers on pathological response to neoadjuvant chemotherapy in breast cancer

    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026

    DOI 10.1007/s12094-025-04194-4 PMID 41525036 2 citations (Europe PMC) Source: Europe PMC

  13. Limb Compression Therapy and Chemotherapy-Induced Peripheral Neuropathy in Women With Gynecologic Cancers: A Prospective Self-Controlled Study(NEURO-GLOVE Trial)

    International journal of cancer, 2026

    DOI 10.1002/ijc.70601 PMID 42311202 Open-access full textSource: Europe PMC

  14. Comparison of the pathological complete response between immunohistochemistry HER2 (3 + ) and HER2 (2 + )/ISH + Early-stage breast cancer: a systematic review and meta-analysis

    Cancer Treatment Reviews, 2026

    DOI 10.1016/j.ctrv.2025.103074 PMID 41512603 4 citations (OpenAlex) Source: OpenAlex

  15. Limb compression therapy and chemotherapy-induced peripheral neuropathy in women with gynecologic cancers: A prospective self-controlled study (NEURO-GLOVE Trial)—Updated long-term analysis.

    Journal of Clinical Oncology, 2026

    DOI 10.1200/jco.2026.44.16_suppl.5545 Source: OpenAlex

  16. Topical Diclofenac for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Prospective Real-World Study

    JCO Global Oncology, 2026

    DOI 10.1200/go-26-00151 PMID 42623594 Open-access full textSource: OpenAlex

  17. FDG PET/CT detection of penile root metastasis extending into the shaft from colorectal cancer: A mucinous lesion with a tubular fluid-like appearance

    Médecine Nucléaire, 2026

    DOI 10.1016/j.mednuc.2026.07.001 Source: OpenAlex

  18. Histologic Subtypes, Treatment Patterns, and Survival Outcomes in Cervical Cancer: A Population-based SEER Study

    Acta haematologica oncologica Turcica., 2026

    DOI 10.4274/ahot.galenos.2026.2026-7-1 Open-access full textSource: OpenAlex

  19. Impact of Zinc Supplementation and Topical Clobetasol on the Prevention of Regorafenib-Induced Hand-Foot Skin Reaction: The ZINCLO-HAND Study

    JCO Oncology Practice, 2026

    DOI 10.1200/op-26-00226 Source: OpenAlex

  20. 2914eP Association between quality of life and sleep disturbances, anxiety, depression, and fatigue during and after (neo)adjuvant taxane-based chemotherapy in breast cancer patients

    Annals of Oncology, 2025

    DOI 10.1016/j.annonc.2025.08.3526 Open-access full textSource: OpenAlex

  21. 3060eP Immunomodulatory effect of cisplatin versus carboplatin on tumor microenvironment and anti-PD-1 response: A multicenter real-world analysis

    Annals of Oncology, 2025

    DOI 10.1016/j.annonc.2025.08.3673 Open-access full textSource: OpenAlex

  22. Immunomodulatory Effect of First-Line Cisplatin Versus Carboplatin in Response to Second-Line Nivolumab Therapy in Metastatic Non-Small Cell Lung Cancer

    Cancer Investigation, 2025

    DOI 10.1080/07357907.2025.2598042 PMID 41451788 Source: OpenAlex

  23. <i>NOTCH1</i>: A Potential New Biomarker in the Era of Immunotherapy?

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2025

    DOI 10.1200/jco-25-00829 PMID 40934460 1 citation (Europe PMC) Open-access full textSource: Europe PMC

  24. Comments on "Folic acid deficiency as a modifiable risk factor for anastomotic leak in patients undergoing colorectal cancer surgery"

    Updates in surgery, 2025

    DOI 10.1007/s13304-025-02336-5 PMID 40691394 Open-access full textSource: Europe PMC

  25. Reevaluating the prognostic impact of spread through air spaces and lymphovascular invasion in resected non-small cell lung cancer: the role of systemic therapy in survival outcomes

    Updates in surgery, 2025

    DOI 10.1007/s13304-025-02259-1 PMID 40382518 Source: Europe PMC

  26. Concerns and Insights on Timing of Immunotherapy and Radiotherapy in Head and Neck Cancer: A Response to Janopaul-Naylor Et Al

    Head & neck, 2025

    DOI 10.1002/hed.27975 PMID 39445634 Open-access full textSource: Europe PMC

  27. Assessment of the CALLY Index, a Novel Immunonutrivite Marker, in Perioperatively Treated Gastric Cancer Patients

    Gazi Medical Journal, 2025

    DOI 10.12996/gmj.2024.4197 9 citations (OpenAlex) Open-access full textSource: OpenAlex

  28. Evaluation of treatment protocols based on the ESMO-magnitude of clinical benefit scale for gastrointestinal system cancers and their relationship with reimbursement policies in Turkey

    Journal of Cancer Policy, 2025

    DOI 10.1016/j.jcpo.2025.100590 PMID 40334742 2 citations (OpenAlex) Source: OpenAlex

  29. Efficacy and safety of omitting 5-fluorouracil bolus in combination chemotherapy regimens for gastrointestinal cancers: a systematic review and meta-analysis

    Expert Opinion on Drug Safety, 2025

    DOI 10.1080/14740338.2025.2527962 PMID 40590359 2 citations (OpenAlex) Open-access full textSource: OpenAlex

  30. Prognostic impact of preoperative cachexia in patients undergoing major hepatopancreatobiliary surgery for malignancy

    Clinical Nutrition, 2025

    DOI 10.1016/j.clnu.2025.07.037 PMID 40945486 Source: OpenAlex

  31. 2881P Integrating inflammatory, nutritional, and sarcopenia-based biomarkers for predicting pathological response in rectal cancer patients receiving total neoadjuvant therapy: A regression and AI-supported approach

    Annals of Oncology, 2025

    DOI 10.1016/j.annonc.2025.08.3493 Open-access full textSource: OpenAlex

  32. 2864P Assessment of inflammation, nutrition and cachexia-related indices to predict 90-day mortality in hospitalized cancer patients

    Annals of Oncology, 2025

    DOI 10.1016/j.annonc.2025.08.3476 Open-access full textSource: OpenAlex

  33. 456eP Comparison of the pathological complete response to neoadjuvant therapy between immunohistochemistry HER2 (3+) and HER2 (2+)/ISH+ early stage breast cancer: A systemic review and meta-analysis

    Annals of Oncology, 2025

    DOI 10.1016/j.annonc.2025.08.879 Open-access full textSource: OpenAlex

  34. 2814P AI-supported evaluation of clinical and biological risk indicators in cancer patients with unplanned hospitalisations

    Annals of Oncology, 2025

    DOI 10.1016/j.annonc.2025.08.3426 Open-access full textSource: OpenAlex

  35. Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study

    Journal of Chemotherapy, 2024

    DOI 10.1080/1120009x.2024.2366683 PMID 38904164 1 citation (Europe PMC) Source: OpenAlex

  36. Effect of HER2/CEP17 ratio on survival in metastatic HER2-positive gastric cancer, multicenter study

    Clinical and Translational Oncology, 2024

    DOI 10.1007/s12094-024-03410-x PMID 38451412 Source: ORCID

  37. Niraparib-induced pure red cell aplasia

    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2024

    DOI 10.1177/10781552231197808 PMID 37642988 Source: Europe PMC

  38. Evaluation of Volumetric Magnetic Resonance Imaging in Determining the Indication for Total Neoadjuvant Therapy in Rectal Cancer

    Journal of gastrointestinal cancer, 2024

    DOI 10.1007/s12029-024-01138-z PMID 39532765 2 citations (Europe PMC) Source: Europe PMC

  39. Visceral obesity and sarcopenia as predictors of efficacy and hematological toxicity in patients with metastatic breast cancer treated with CDK 4/6 inhibitors

    Cancer chemotherapy and pharmacology, 2024

    DOI 10.1007/s00280-024-04641-z PMID 38436714 18 citations (Europe PMC) Source: Europe PMC

  40. Comparison of the second-line treatment efficacy in advanced gastric cancer patients previously treated with taxane-based triplet chemotherapy: a Turkish Oncology Group Study

    Current medical research and opinion, 2024

    DOI 10.1080/03007995.2024.2366430 PMID 38857167 Open-access full textSource: Europe PMC

  41. Oxaliplatin‑induced changes in splenic volume and liver fibrosis indices: retrospective analyses of colon cancer patients receiving adjuvant chemotherapy

    Journal of chemotherapy (Florence, Italy), 2024

    DOI 10.1080/1120009x.2023.2246786 PMID 37578138 2 citations (Europe PMC) Source: Europe PMC

  42. Impact of Serum GDF-15 and IL-6 on Immunotherapy Response in Cancer: A Prospective Study

    Cancers, 2024

    DOI 10.3390/cancers16244146 PMID 39766045 10 citations (OpenAlex) Open-access full textSource: OpenAlex

  43. Can artificial intelligence provide accurate and reliable answers to cancer patients’ questions about cancer pain? Comparison of chatbots based on ESMO cancer pain guideline

    memo - Magazine of European Medical Oncology, 2024

    DOI 10.1007/s12254-023-00954-6 11 citations (OpenAlex) Source: OpenAlex

  44. The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer

    Medicine, 2024

    DOI 10.1097/md.0000000000038828 PMID 39058877 2 citations (OpenAlex) Open-access full textSource: OpenAlex

  45. Management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction: the Neo-AEGIS trial

    The Lancet. Gastroenterology & hepatology, 2024

    DOI 10.1016/s2468-1253(23)00376-x PMID 38215772 Source: OpenAlex

  46. The Prognostic Value of the Preoperative Geriatric Nutritional Risk Index in Elderly Colon Cancer Patients Underwent Curative Resection

    Acta Oncologica Turcica, 2024

    DOI 10.5505/aot.2023.03779 Open-access full textSource: OpenAlex

  47. Kansere Bağlı Alt Ekstremite Ödemi

    2024

    DOI 10.5152/7614 Source: OpenAlex

  48. Alt Ekstremite Ödemi

    2024

    DOI 10.5152/7600 Source: OpenAlex

  49. 1483P Prospective observational study to assess the prophylactic effect of topical diclofenac in preventing the development of hand foot syndrome in patients with colorectal and gastric cancer on capecitabine therapy

    Annals of Oncology, 2024

    DOI 10.1016/j.annonc.2024.08.1548 Open-access full textSource: OpenAlex

  50. Retrospective Evaluation of the Efficacy and Safety of Niraparib Maintenance; Real World Data on Turkish Early-Access Program

    Eurasian Journal of Medical Investigation, 2024

    DOI 10.14744/ejmi.2024.66856 Open-access full textSource: OpenAlex